Європейський Союз - болгарська - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - Средства за дерматит, с изключение на кортикостероиди - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Європейський Союз - болгарська - EMA (European Medicines Agency)

sanofi winthrop industrie - инсулин лиспро - Захарен диабет - Лекарства, използвани при диабет - За лечение на възрастни и деца със захарен диабет, които се нуждаят от инсулин за поддържане на нормална глюкозна хомеостаза. Инсулин лиспро sanofi е показан и за първоначалната стабилизация на захарния диабет.

Європейський Союз - болгарська - EMA (European Medicines Agency)

janssen-cilag international nv - guselkumab - псориазис - Имуносупресори - plaque psoriasis tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritis tremfya, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (dmard) therapy (see section 5.

Європейський Союз - болгарська - EMA (European Medicines Agency)

janssen-cilag international nv - esketamine хидрохлорид - Депресивно Разстройство - Други антидепресанти - spravato, в съчетание с ssri или СИОЗН, предназначени за възрастни с резистентной към терапията на депресивните разстройства, които не са отговорили на поне две различни техники за лечение с антидепресанти в днешно умерени и тежки депресивни епизода.

Європейський Союз - болгарська - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant adenovirus type 26 (ad26) encoding the glycoprotein (gp) of the ebola virus zaire (zebov) mayinga strain - Хеморагична Треска Ебола - Ваксини - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Європейський Союз - болгарська - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant modified vaccinia ankara bavarian nordic virus encoding the: ebola virus zaire (zebov) mayinga strain glycoprotein (gp); ebola virus sudan gulu strain gp; ebola virus taï forest strain nucleoprotein and the marburg virus musoke strain gp - Хеморагична Треска Ебола - Ваксини - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Європейський Союз - болгарська - EMA (European Medicines Agency)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - Ваксини - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. Използването на тази ваксина трябва да бъде приложена в съответствие с официалните препоръки.

Європейський Союз - болгарська - EMA (European Medicines Agency)

janssen-cilag international n.v.    - amivantamab - Карцином, недребноклетъчен белодроб - Антинеопластични средства - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Європейський Союз - болгарська - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - Множествена миелома - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Європейський Союз - болгарська - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - Множествена миелома - Антинеопластични средства - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.